Trends & Forecasts

We ask an analyst how pharma companies can weather the volatile economic environment and the Trump administration’s tariffs.

Trump continues to send shockwaves through the industry. We look at FDA disruption, tariffs, funding volatility, and more.

Many US researchers are at odds with the imposition of Trump’s political agendas. EU member states are looking to take advantage.

Can making clinical trials more family friendly help increase the number of female participants?

As mental health disorders escalate, pharmaceutical innovators can harness advanced tools to accelerate much-needed treatments.

Our latest news roundup reports on Roche’s US investment, a lawsuit against Vertex Pharmaceuticals, and more.

EMA reflection paper considers elimination of routine comparative efficacy studies for biosimilars.

Trump signs executive order on lowering drug prices and amends Medicare price negotiation for small molecule drugs.

The political situation in the US and its impact on science and medicine is changing rapidly. Here’s a quick look at the latest developments.

We dive into the archive of 2022 for insight and inspiration – this time with Kowid Ho